CAS: 676129-92-3; Desvaleroyl Valsartan
物理性质
- 沸点598.2±60.0 °C at 760 mmHg
- 闪点315.6±32.9 °C
- 密度1.3±0.1 g/cm3
- pKa:2.29±0.13(预测)
- PSA:103.79
- LogP:3.52
- 折射率1.609
- 蒸汽压0.0±1.8 mmHg at 25°C
- 溶解性DMF:3.0(Max Conc. mg/mL);8.54(Max Conc. Mm) DMSO:5.0(Max Conc. mg/mL);14.23(Max Conc. Mm) Ethanol:1.0(Max Conc. mg/mL);2.85(Max Conc. Mm)
- 外观形态白色至类白色固体
- 储存条件Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
- 产品应用该化合物是II型血管(AT1)受体对立物VALSARTON的商业制剂中发现的一种潜在的杂质,是一种在酸性条件下形成的降解产物.
MSDS等安全信息
上下游产品
CAS号137862-53-4 缬沙坦合成工艺路线路线简述
📜缬沙坦置于水,Sodium Hydroxide体系中,化学反应 24.0H,反应生成 N-[[2'(-(1H-四唑-5-基)[1,1'(-联苯]-4-基]甲基]-L-缬氨酸
参考文献:Isolation And Characterization Of Novel Degradation Products Of Valsartan By NMR And High Resolution Mass Spectroscopy: Development And Validation Of Valsartan By Uplc
标题:Isolation And Characterization Of Novel Degradation Products Of Valsartan By NMR And High Resolution Mass Spectroscopy: Development And Validation Of Valsartan By Uplc
摘要:Valsartan被用于治疗高血压,心力衰竭和糖尿病肾病.它经过了酸性,碱性和过氧化物介导的氧化强制降解.强制降解是按照ich指南q1A(R2)-新药物物质和产品的稳定性测试进行的.在过氧化物介导的水解下,该药物是惰性的,碱性水解形成了两种降解物(dp-Val-1,Dp-Val-2),酸性水解形成了一种降解物(dp-Val-3).这些降解物最初是通过lc-Ms鉴定并通过质量介导纯化系统分离的.dp-Val-1和dp-Val-3已经报道,但它们的结构尚未通过2D NMR研究得到确认.dp-Val-2是一种新的降解物,其结构已通过高分辨率质谱和1D,2D NMR光谱的实质分析得到阐明.dp-Val-1由旋转异构体混合物组成,这个假设已通过可变温度NMR(vt-NMR)得到确认.开发并验证了一种稳定性指示rp-Uplc方法,用于测定valsartan Api药物的含量.在acquity Beh C-18 2.1x100Mm,1.7μm柱上验证了valsartan Uplc方法,运行时间缩短至6分钟,并按照监管指南在特异性,准确性,线性,精密度,检测限和定量限方面进行了验证.
DOI:10.14233/ajchem.2020.22526
海关参考信息
- 2902300000-甲苯
2905121000-正丙醇
2905130000-正丁醇
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-7728024-B2
优先权日:2005-07-11
标 题:Metal salts of 2′-(1H-Tetrazol-5yl)-1.1′-biphenyl-4-carboxaldehyde
发明人：SEDELMEIER GOTTFRIED; GRIMLER DOMINIQUE
权利人:NOVARTIS AG
摘要:The invention relates to a method or process for the manufacture of blood pressure lowering agents, such as valsartan, novel intermediates as well as process steps in said synthesis. The method or process leads via the novel intermediate salts of the formula IA, n nor a tautomer thereof, wherein [kat] n+ is a cation and n is 1, 2, 3, 4, 5 or 6.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Monosilio S, Filomena D, Luongo F, Sannino M, Cimino S, Neccia M, Mariani MV, Birtolo LI, Benedetti G, Tonti G, Pedrizzetti G, Vizza CD, Maestrini V, Agati L. Cardiac and Vascular Remodeling After 6 Months of Therapy With Sacubitril/Valsartan: Mechanistic Insights From Advanced Echocardiographic Analysis. Front Cardiovasc Med. 2022 May 18;9:883769. doi: 10.3389/fcvm.2022.883769.
2: Minotti G, Menna P, Camilli M, Salvatorelli E, Levi R. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio- oncology. Adv Pharmacol. 2022;94:365-409. doi: 10.1016/bs.apha.2022.02.002. Epub 2022 Mar 30. 10(6):415-427. doi: 10.1016/j.jchf.2022.01.020. Epub 2022 Apr 6. 10(6):380-392. doi: 10.1016/j.jchf.2022.04.006.
156:111303. doi: 10.1016/j.foodres.2022.111303. Epub 2022 May 7.
合成参考文献
参考文献:10.1016/j.jpba.2009.05.024
摘要:Sampath A, Reddy AR, Yakambaram B, Thirupathi A, Prabhakar M, Reddy PP, Reddy VP. Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist. Journal of Pharmaceutical and Biomedical Analysis. 2009 Oct;50(3):405–12. doi: 10.1016/j.jpba.2009.05.024.
📝 需求与反馈
尽可能描述清楚需求与问题信息
